Welcome to iAluRil.co.uk
EACH PRE-FILLED SYRINGE IS FOR ONE PATIENT ONLY.
IALURIL® Prefill – 50 ml pre-filled syringe is steam sterilized.
IALURIL® Prefill – 50 ml pre-filled syringe is Latex Free.
Luer-Lock Adapter is sterilized using ethylene oxide.1
Ialuadapter® is sterilized using Gamma ray1
iAluRil contains three active components: 800 mg/50 ml sodium hyaluronate (1.6%), 1 g /50 ml sodium chondroitin sulfate (2%) and calcium chloride (0.87%).
iAluRil can be used for the treatment of:
– Interstitial cystitis/painful bladder syndrome
– Recurrent urinary tract infections
– Chemical-/radiation-induced cystitis (including BCG)
iAluRil® is the first intravesical GAG replacement therapy to combine one of the most abundant sulfated GAG molecules located on the bladder wall,2 chondroitin sulfate, with the most integral component of the GAG layer,3 hyaluronic acid. This combination is designed to facilitate faster and more effective restoration of the bladder epithelium.
iAluRil contains 20-times the concentration of hyaluronic acid compared with the conventional therapy (Cystistat®; Teva UK Ltd, West Yorkshire, UK), which contains 0.08% hyaluronic acid, this increase allows for more association sites for a core protein to bind to. Through a link protein the core protein can bind to sulfated glycosaminoglycans such as chondroitin sulfate. Chondroitin sulfate then functions to bind water molecules on the surface of the epithelial lining of the bladder in order to maintain the waterproof and impermeable nature of a healthy bladder.2 Therefore, by increasing the concentration of hyaluronic acid it ultimately increases the number of water molecules bound providing more help in maintaining the healthy state of the bladder.
Available in hospital and community practice. Now available on FP10.
1) iAluRil Prefill Patient Information. 2) Hurst RE et al. Functional and Structural Characteristics of the Glycosaminoglycans of the Bladder Luminal Surface. J Urol 1987; 138 (2): 433-437. 3) Stryer L. Biochemistry – 4th Edition. W.H. Freeman & Company; 1995. 4. Parsons CL et al. Abnormal Sensitivity to Intravesical Potassium in Interstitial Cystitis and Radiation Cystitis. Neurourol Urodyn 1994; 13(5): 515-520. 5. Damiano R et al. Prevention of Recurrent Urinary Tract Infections by Intravesical Administration of Hyaluronic Acid and Chondroitin Sulfate: a Placebo-Controlled Randomised Trial. Eur Urol 2011; 59(4): 645-651.
DEPENDABLE SUPPLY CHAIN.
For further information please call: 01730 231148,
email: firstname.lastname@example.org or visit www.aspirepharma.co.uk